Figure 2. Meta-Analysis of Treatment-Related High-Grade Adverse Events and Discontinuations With Nivolumab and Ipilimumab vs Nivolumab Alone.
A, Forest plot and meta-analysis of cumulative grade 3 to 4 adverse events with nivolumab and ipilimumab vs nivolumab alone show substantial increase in severe adverse events with the combination (pooled odds ratio, 1.84; 95% CI, 1.47-2.31; P < .001; I2 = 0%). B, Forest plot and meta-analysis of treatment-related discontinuation with nivolumab and ipilimumab vs nivolumab alone show nearly 2 times greater odds of treatment-related discontinuation with the combination (pooled odds ratio, 1.96; 95% CI, 1.45-2.66; P < .001; I2 = 2%).